Bio-Rad [BIO.B] vs Masimo [MASI] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bio-Rad Laboratories, Inc. wins in 13 metrics, Masimo Corporation wins in 7 metrics, with 0 ties. Bio-Rad Laboratories, Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bio-Rad Laboratories, Inc. | Masimo Corporation | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.75 | 46.47 | Bio-Rad Laboratories, Inc. |
| Price-to-Book Ratio | 1.08 | 12.89 | Bio-Rad Laboratories, Inc. |
| Debt-to-Equity Ratio | 18.58 | 77.55 | Bio-Rad Laboratories, Inc. |
| PEG Ratio | -0.05 | 27.03 | Masimo Corporation |
| EV/EBITDA | 18.37 | 28.15 | Bio-Rad Laboratories, Inc. |
| Profit Margin (TTM) | 29.42% | -9.92% | Bio-Rad Laboratories, Inc. |
| Operating Margin (TTM) | 8.87% | 18.52% | Masimo Corporation |
| EBITDA Margin (TTM) | 8.87% | 18.52% | Masimo Corporation |
| Return on Equity | 10.84% | 23.43% | Masimo Corporation |
| Return on Assets (TTM) | 1.67% | 8.86% | Masimo Corporation |
| Free Cash Flow (TTM) | $374.60M | $193.10M | Bio-Rad Laboratories, Inc. |
| 1-Year Return | 21.62% | 9.82% | Bio-Rad Laboratories, Inc. |
| Price-to-Sales Ratio (TTM) | 3.13 | 6.12 | Bio-Rad Laboratories, Inc. |
| Enterprise Value | $7.93B | $9.72B | Masimo Corporation |
| EV/Revenue Ratio | 3.07 | 6.37 | Bio-Rad Laboratories, Inc. |
| Gross Profit Margin (TTM) | 49.80% | 59.95% | Masimo Corporation |
| Revenue per Share (TTM) | $95 | $28 | Bio-Rad Laboratories, Inc. |
| Earnings per Share (Diluted) | $27.85 | $3.84 | Bio-Rad Laboratories, Inc. |
| Beta (Stock Volatility) | 1.16 | 1.20 | Bio-Rad Laboratories, Inc. |
| Short % of Float | 0.01% | 6.81% | Bio-Rad Laboratories, Inc. |
Bio-Rad Laboratories, Inc. vs Masimo Corporation Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. | 0.00% | 13.73% | 1.57% | 13.11% | -2.11% | -2.11% |
| Masimo Corporation | 0.07% | 0.03% | 0.29% | 1.89% | 25.69% | 40.28% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. | 21.62% | -18.04% | -49.03% | 106.20% | 145.92% | 353.96% |
| Masimo Corporation | 9.82% | 9.28% | -15.51% | 257.33% | 509.04% | 791.36% |
Performance & Financial Health Analysis: Bio-Rad Laboratories, Inc. vs Masimo Corporation
| Metric | BIO.B | MASI |
|---|---|---|
| Market Information | ||
| Market Cap | $8.08B | $9.36B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 10 | 558,463 |
| 90 Day Avg. Volume | 17 | 1,362,548 |
| Last Close | $304.15 | $178.72 |
| 52 Week Range | $244.54 - $321.12 | $125.94 - $179.00 |
| % from 52W High | -5.28% | -0.16% |
| All-Time High | $818.60 (Sep 06, 2021) | $305.21 (Nov 15, 2021) |
| % from All-Time High | -62.85% | -41.44% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.12% |
| Quarterly Earnings Growth | 0.04% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.29% | -0.10% |
| Operating Margin (TTM) | 0.09% | 0.19% |
| Return on Equity (TTM) | 0.11% | 0.23% |
| Debt to Equity (MRQ) | 18.58 | 77.55 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $276.16 | $13.84 |
| Cash per Share (MRQ) | $57.08 | $2.92 |
| Operating Cash Flow (TTM) | $532.20M | $217.80M |
| Levered Free Cash Flow (TTM) | $256.55M | $316.41M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Bio-Rad Laboratories, Inc. vs Masimo Corporation
| Metric | BIO.B (Apr 26, 2026) | MASI (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.75 | 46.47 |
| Forward P/E | N/A | 27.03 |
| PEG Ratio | -0.05 | 27.03 |
| Price to Sales (TTM) | 3.13 | 6.12 |
| Price to Book (MRQ) | 1.08 | 12.89 |
| Market Capitalization | ||
| Market Capitalization | $8.08B | $9.36B |
| Enterprise Value | $7.93B | $9.72B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.07 | 6.37 |
| Enterprise to EBITDA | 18.37 | 28.15 |
| Risk & Other Metrics | ||
| Beta | 1.16 | 1.20 |
| Book Value per Share (MRQ) | $276.16 | $13.84 |
Financial Statements Comparison: Bio-Rad Laboratories, Inc. vs Masimo Corporation
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | BIO.B (2025) | MASI (2025) |
|---|---|---|
| Revenue/Sales | 2.58B | 1.53B |
| Cost of Goods Sold | 1.24B | 581.70M |
| COGS % of Revenue | 48.1% | 38.1% |
| Gross Profit | 1.34B | 945.20M |
| Gross Margin | 51.9% | 61.9% |
| Research & Development | 275.60M | 126.40M |
| Operating Income (EBIT) | 218.60M | 312.80M |
| Operating Margin | 8.5% | 20.5% |
| EBITDA | 480.70M | 355.00M |
| EBITDA Margin | 18.6% | 23.2% |
| Pre-Tax Income | 995.50M | 272.60M |
| Pre-Tax Income % of Revenue | 38.5% | 17.9% |
| Income Tax | 235.60M | 64.90M |
| Income Tax % of Revenue | 9.1% | 4.3% |
| Net Income (Profit) | 759.90M | -151.50M |
| Profit Margin | 29.4% | -9.9% |
Balance Sheet & Liquidity Metrics
| Metric | BIO.B (2025) | MASI (2025) |
|---|---|---|
| Cash & Equivalents | 529.80M | 152.30M |
| Total Current Assets | 2.91B | 926.00M |
| Total Current Assets % of Revenue | 112.5% | 60.6% |
| Total Current Liabilities | 517.00M | 371.60M |
| Total Current Liabilities % of Revenue | 20.0% | 24.3% |
| Long-Term Debt | 1.35B | 544.90M |
| Long-Term Debt % of Revenue | 52.2% | 35.7% |
| Total Shareholders Equity | 7.45B | 721.20M |
| Retained Earnings | 8.18B | 1.34B |
| Retained Earnings % of Revenue | 316.5% | 87.7% |
| Property, Plant & Equipment | 1.49B | 237.20M |
Cash Flow Statement Comparison
| Metric | BIO.B (2025) | MASI (2025) |
|---|---|---|
| Operating Cash Flow | 1.25B | 198.40M |
| Operating Cash Flow % of Revenue | 48.4% | 13.0% |
| Capital Expenditures | -157.50M | 200,000 |
| Free Cash Flow | 374.60M | 193.10M |
| FCF Margin | 14.5% | 12.6% |
| Debt Repayment | -500,000 | -1.28B |
| Common Stock Repurchase | -295.50M | -363.70M |
Short Interest & Institutional Ownership Analysis
| Metric | BIO.B | MASI |
|---|---|---|
| Shares Short | 14 | 3.25M |
| Short Ratio | 0.16 | 1.68 |
| Short % of Float | 0.01% | 6.81% |
| Shares Outstanding | 26.99M | 52.10M |
| Float Shares | 21.13M | 47.45M |
| % Held by Insiders | 98.13% | 5.00% |
| % Held by Institutions | 0.06% | 109.04% |
| % Held by Public | 1.81% | -14.04% |
Dividend Analysis & Yield Comparison: Bio-Rad Laboratories, Inc. vs Masimo Corporation
| Metric | BIO.B | MASI |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |